Journal of Pain and Symptom Management
Volume 38, Issue 4 , Pages e5-e8 , October 2009

Intravenous Naloxone Plus Transdermal Buprenorphine in Cancer Pain Associated with Intractable Cholestatic Pruritus

References 

  1. Tarcatu D, Tamasdan C, Moryl N, Obbens E. Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. J Opioid Manag. 2007;3:167–170
  2. Chang Y, Golkar L. The use of naltrexone in the management of severe generalized pruritus in biliary atresia: report of a case. Pediatr Dermatol. 2008;25:403–404
  3. Juby LD, Wong VS, Losowsky MS. Buprenorphine and hepatic pruritus. [abstract] Br J Clin Pract. 1994;48:331
  4. Kiefel JM, Cooper ML, Bodnar RJ. Serotonin receptor subtype antagonists in the medial ventral medulla inhibit mesencephalic opiate analgesia. Brain Res. 1992;597:331–338
  5. Larijani GE, Goldberg ME, Rogers KH. Treatment of opioid-induced pruritus with ondansetron: report of four patients. Pharmacotherapy. 1996;16:958–960
  6. Jones EA, Bergasa NV. The pruritus of cholestasis and the opioid system. JAMA. 1992;268:3359–3362
  7. Raderer M, Muller CH, Scheithauer W. Ondansetron for pruritus due to cholestasis. [letter] N Engl J Med. 1994;330:1540
  8. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists; effectiveness of ondansetron. Pain. 1995;61:33–37
  9. Jones EA, Bergasa NV. The pruritus of cholestasis. From bile acids to opiate agonists. Hepatology. 1990;11:884–887
  10. Bergasa NV, Jones EA. The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology. 1995;108:1582–1588
  11. Choi JH, Lee J, Bishop MJ. Epidural naloxone reduces pruritus and nausea without affecting analgesia by epidural morphine in bupivacaine. Can J Anaesth. 2000;47:33–37
  12. Andersen LW, Friedberg M, Lokkegaard N. Naloxone in the treatment of uremic pruritus: a case history. Clin Nephrol. 1984;21:355–356
  13. Tejwani GA, Rattan AK. The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat. Anesth Analg. 2002;94:1542–1546
  14. Greenwald MK, Johanson CE, Moody DE, et al. Effects of buprenorphine maintenance dose on m-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28:2000–2009
  15. Bergasa NV, Talbot TL, Alling DW, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology. 1992;102:544–549
  16. Knape JTA. Early respiratory depression resistant to naloxone following epidural buprenorphine. Anesth. 1986;64:382–384
  17. Bickel WK, Amass L. Buprenorphine treatment in opioid dependence: a review. Exp Clin Psychopharmacol. 1995;3:477–489
  18. Friedman JD, Dello Buono FA. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacother. 2001;35:85–91

PII: S0885-3924(09)00638-1

doi: 10.1016/j.jpainsymman.2009.05.008

Journal of Pain and Symptom Management
Volume 38, Issue 4 , Pages e5-e8 , October 2009

Article Tools